1. Background {#sec1}
=============

Use of electronic medical records (EMRs) has grown dramatically over the last decade. Traditional methods for identifying comorbidity data in EMRs for use in clinical research have relied primarily on comprehensive manual chart review. While highly sensitive for extracting data from EMR systems, they are very costly and time consuming as they need to be performed by trained chart abstractors \[[@B1]\].

The objective of the current study was to develop and validate an efficient and reliable algorithm to identify comorbidities among advanced non-small cell lung cancer (NSCLC) patients using relatively simple queries and text field searches of EMR data.

In 2010, cancer of the lung or bronchus resulted in approximately 222,000 new cases and 167,000 deaths within the United States \[[@B2]\]. Approximately 85% of lung cancer patients will have NSCLC; most will have advanced stage disease at the time of diagnosis, and 5-year survival is less than 10% in this patient population \[[@B3], [@B4]\].

The median age of NSCLC patients is now slightly less than 70 years \[[@B5]\], and 60% of cases occur in patients ≥65 years \[[@B6]\]. As a result, patients often present with several concurrent comorbid conditions that may impair organ function \[[@B7], [@B8]\] and result in reduced therapeutic benefit from chemotherapy \[[@B9]\]. In addition, common risk factors for NSCLC, such as smoking or excessive alcohol use \[[@B10]\], also place patients at greater risk for other serious medical conditions such as heart disease, chronic obstructive pulmonary disease (COPD), other cancers, and stroke.

The presence of NSCLC together with a serious comorbid condition has the potential to impact treatment decision making and clinical outcomes \[[@B11]\]. Retrospective observational research on NSCLC outcomes using EMR data should thus include information on patients\' comorbid conditions, making the accurate and efficient identification of comorbidity data vital. Information on adapting a clinical comorbidity index for use with ICD-9-CM administrative databases is available in the medical literature \[[@B1]\]. Lacking in the literature is clarity on whether efficient electronic searches and queries of oncology EMR data can yield similar comorbidity information in the absence of claims data and without costly and lengthy manual chart abstraction.

2. Methods {#sec2}
==========

2.1. Data Sources {#sec2.1}
-----------------

This retrospective study utilized data from US Oncology\'s EMR system iKnowMed (iKM). iKM is an oncology-specific EMR system that captures outpatient practice encounter history for patients under care including (but not limited to) laboratory, diagnosis, therapy administration, line of therapy, staging, comorbidities, and performance status information. This product is being implemented across the US Oncology Comprehensive Strategic Alliance (CSA) network. iKM currently is used by more than 900 community-based oncology providers. For the time-frame of this study, iKM was active in approximately 82% of the CSA network.

Due to new initiatives to utilize an electronic medical record system, US Oncology began to implement this electronic record early on in US Oncology\'s history. Initially, the EMR was designed to capture the information that was previously collected on the paper record. Currently, US Oncology researchers have the ability to conduct retrospective studies and gain access to the electronic data by submitting a request to the US Oncology Institutional Review Board (IRB). This current study was submitted to and approved by the US Oncology IRB. There was minimal patient risk related to this retrospective study, and patient confidentiality was rigorously maintained per US Oncology policies. Only US Oncology employees on the study team had access to the data and were involved in data manipulation and analysis. Waiving informed consent did not adversely affect patient rights as they were unlikely to directly benefit from this study. Only the minimum number of variables necessary to accomplish the goals of this project were extracted. Only data that fell within the study time period were used and all results are reported in the aggregate. Electronic chart reviews were conducted only for the purpose of validating data that were abstracted through programmatic queries of the iKnowMed database.

2.2. Patient Selection Criteria and Characteristics {#sec2.2}
---------------------------------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, this study included advanced NSCLC patients who initiated a first- or second-line chemotherapy regimen in the 30-month period from July 1, 2006 through June 30, 2008. Patients in the 1st line cohort were not included in the 2nd line cohort, even if they initiated 2nd line therapy during the 30-month period. All patients received care at a US Oncology Network practice utilizing iKM capabilities. NSCLC disease was required to be Stage IIIB or IV or recurrent (defined as disease that was initially diagnosed as early stage that progressed to metastatic disease). Patients who were enrolled on formal IRB approved clinical trials were excluded from this analysis as were any patients receiving care for other primary cancers during the study time period.

*Phase 1: Algorithm for Identification of Comorbidities*To efficiently identify specific comorbid conditions, programmatic queries were applied to standardized fields within the EMR (i.e., concomitant illness tables, specific diagnosis tables, review of symptoms, physical examination tables, and past medical history table). To supplement the programmatic queries, keyword searches (see the appendix) were conducted of available text-based fields (e.g., dictation notes or nurse progress notes). There were no time restrictions placed on the queries or text field searches meaning comorbidities found at any time in the EMR were eligible.

*Phase 2: Validation of Algorithm*We evaluated the reliability of the EMR query/text field search by comparing comorbidity status of patients as identified via the query/text field search algorithm to the comorbidity status as identified via the comprehensive chart review (the gold standard). To do this, the algorithm was used to identify the patients in the study sample without comorbidities. Seven groups of patients were created by randomly sampling from among these patients: one group (*N* = 150) had no evidence of any comorbidities while 6 groups (*N* = 50 each) did not have evidence of a single prespecified comorbidity. For all patients in these 7 groups, comprehensive chart reviews (i.e., the gold standard) were conducted to verify that they were truly negative for comorbidities. Reliability (as demonstrated by negative predictive value) of the algorithm was calculated as follows: $$\begin{aligned}
 & {\text{Negative}{\,\,}\text{predictive}{\,\,}\text{value}} \\
 & {\quad\quad = \frac{\text{True}{\,\,}\text{negatives}}{\left( \text{True}{\,\,}\text{negatives}{\,\,} + {\,\,}\text{False}{\,\,}\text{negatives} \right)}.} \\
\end{aligned}$$ Negative predictive values greater than 80% were considered to be acceptable. Negative predictive values greater than 90% were considered to be good quality.

2.3. Statistics {#sec2.3}
---------------

Negative predictive values between specific groups were compared using an exact version of Pearson\'s chi-square test. 95% confidence intervals were calculated using an exact test for proportions. All analyses were run in SAS version 8.2 (Cary, North Carolina).

3. Results {#sec3}
==========

3.1. Patient Disposition {#sec3.1}
------------------------

[Figure 1](#fig1){ref-type="fig"} summarizes the study population selection. During the study period, 2,992 patients with advanced NSCLC received chemotherapy at a US Oncology Network site that had iKM EMR capabilities. Of these, 2,513 patients (84%) were included in this study. Patient demographic and clinical characteristics as well as comorbidity status (as documented via the EMR search algorithm) are summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Concordance between Comprehensive Electronic Chart Review and EMR Search Algorithm {#sec3.2}
---------------------------------------------------------------------------------------

The measured reliability of the search algorithm is summarized in [Table 2](#tab2){ref-type="table"}. Of the 150 patients randomly chosen who were negative for all selected comorbidities via search algorithm, 16 were false negatives (via "gold standard" comprehensive chart review), for a negative predictive value of 89%. Within the 6 groups of randomly selected patients (*N* = 50 each) who were negative for specific comorbidities via search algorithm, negative predictive values ranged from 82% for diabetes (9 of 50 patients were found to have diabetes on chart review) to 100% for cerebrovascular disease and were found to differ significantly in the six disease-specific samples (*P* = .007). Considering the 450 patients from all groups, the overall negative predictive value was 92% (36 of 450 were found to have evidence of comorbidities on chart review).

4. Conclusions {#sec4}
==============

Results of the current study suggest that efficient programmatic queries and text field searches of EMR data may provide reliable data on comorbid conditions among cancer patients. Among this population of advanced NSCLC patients, the rate of comorbidities was 22%. The most prevalent comorbidity, as expected, was COPD. This is consistent with research in operable patients with NSCLC, which has found rates of COPD as high as 50% \[[@B12]\].

Traditional methods for identifying comorbidity data in EMRs for use in clinical research have relied primarily on comprehensive manual chart review. While this study relied on chart reviews to be a highly sensitive gold standard for extracting data from EMR systems, we also characterized them as costly and time consuming as they were conducted by nurses trained in chart abstraction over the course of several weeks. As EMR data sources become more widely utilized in health services and outcomes research, it will be important to develop methods of electronically searching the data in ways that are as clinically accurate but provide significant savings in both time and money compared to manual chart reviews.

Using an algorithm that incorporated programmatic queries and keyword searches of US Oncology\'s cancer-specific EMR system (iKM), we were able to reliably and accurately identify comorbidities. In a validation study using comprehensive electronic chart reviews, the algorithm yielded an acceptable false negative rate (8%).

The benefits of search algorithms of electronic records compared with comprehensive manual chart reviews have been previously reported \[[@B1], [@B13]--[@B15]\]. These include the reduction in time and expense for data extraction as well as the identification of data in free-text chart notes that otherwise would be difficult to locate. While previous papers have focused on the experience of single institutions, our experience suggests that implementation within a large oncology network is feasible. Refinement of search algorithms will continue to grow in importance as the use of EMRs by the broader oncology community expands. The lack of standard reporting requirements has been an important limitation of attempts to use EMRs for clinical research purposes \[[@B16]\]. The validity of the data extracted in the current study reflects the strength of the iKM system in terms of data standardization. Efforts to improve the search algorithm include ongoing collaborations by US Oncology with their physicians to enhance and refine the capture of relevant free-text data and also to ensure the algorithm reflects advances in the field of oncology. US Oncology is also working to improve iKM by defining additional fields their physicians need to capture and document the patients\' clinical information, as well as continuing to train their physicians to enhance documentation and data capture rates.

While the use of oncology-specific EMR data and outpatient claims data provides a very detailed and comprehensive view of the medical oncology setting, a limitation of the study is the likelihood of missing data on comorbidity-specific resource utilization that may occur outside the US Oncology network, particularly those associated with noncancer-related events. Another limitation is that we studied only the negative predictive value of the new algorithm. To ascertain sensitivity would require a different and potentially arduous study design in which one captured sufficiently large numbers of patients with each of the comorbidities via random selection from the population using the gold standard manual chart review process. Our assumption is that given the serious nature of the comorbidities of interest, they were likely to have been reported to the attending physician. It remains for future study whether the comorbidities were subsequently properly captured in iKM.

Comorbidities as defined in the current study relate to physical conditions that are not a part of lung cancer, but that may have an impact on treatment choices, safety, and outcomes. The current search strategy using efficient queries of standardized EMR data may be widely applicable to other oncology settings and research questions. The current report suggests it is possible to extract research data in a reliable and timely manner.
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iKM Search Terms Used in This Study {#sec5}
===================================

1.  DM: Diabetes mellitus

2.  Congestive heart failure

3.  Peripheral vascular disease

4.  Aortic aneurysm

5.  Aortic dissection

6.  Thoracic aneurysm

7.  Abdominal aneurysm

8.  Venous thromboembolism

9.  Myocardial infarction

10. Coronary artery disease

11. CAD

12. HTN

13. Cereb

14. Hemorrhage

15. Cranial

16. Occlusion

17. Embolism

18. Obstruction

19. Stroke

20. Thrombosis

21. Narrowing

22. Transient

23. TCI

24. CVA

25. TIA

26. Chronic glomerulonephritis

27. Nephritis

28. Nephropathy

29. Kidney

30. Renal failure

31. CRI

32. Cirrhosis

33. Hepatitis

34. Portal

35. Liver

36. Hepatic

37. Hepatorenal

38. Varices

39. CPD

40. COPD

41. Chronic and pulmonary

42. Bronchitis.

![Sample selection flow chart. Abbreviations: EMR: electronic medical record. NSCLC: non-small cell lung cancer.](JCE2011-983271.001){#fig1}

###### 

Patient characteristics of study sample (*N* = 2, 513).

                                             *N* (%)
  ------------------------------------------ ---------------
  Line of therapy                            
   First-line                                2004 (80%)
   Second-line                               509 (20%)
                                             
  Age                                        
   Mean (SD)                                 69.7
   Median (range)                            70.7 (30--92)
                                             
  Gender                                     
   Male                                      1378 (55%)
   Female                                    1135 (45%)
                                             
  Stage at diagnosis                         
   I-IIIA                                    538 (24%)
   IIIB-IV                                   1664 (76%)
   Missing                                   311
                                             
  Performance status                         
   0                                         1045 (46%)
   1                                         1032 (46%)
   2+                                        175 (8%)
   Missing                                   261
                                             
  Comorbidity status                         
   Any comorbidity (1+ comorbidities)        553 (22%)
   Specific comorbidities                    
    Moderate/severe renal disease            37 (1.5%)
    Congestive heart failure                 106 (4.2%)
    Chronic obstructive pulmonary disorder   218 (9%)
    Cerebrovascular disease                  33 (1.3%)
    Diabetes                                 162 (6.4%)
    Peripheral vascular disease              113 (4.5%)
    Myocardial infarction                    21 (0.8%)
    Liver disease                            16 (0.6%)

###### 

Measured reliability of algorithm (combination of programmatic queries and key word searches).

  Electronic chart review group                                            True negatives (via chart review)   False negatives (via chart review)   Negative predictive value   95% confidence interval
  ------------------------------------------------------------------------ ----------------------------------- ------------------------------------ --------------------------- -------------------------
  *N* = 450 patients identified as negative via algorithm                  414                                 36                                   0.92                        0.89--0.94
                                                                                                                                                                                
  Subgroup analyses of patients negative for comorbidities via algorithm                                                                                                        
                                                                                                                                                                                
  Group 1: Negative for all comorbidities (*N* = 150)                      134                                 16                                   0.89                        0.83--0.94
  Group 2: Negative for diabetes (*N* = 50)                                41                                  9                                    0.82                        0.69--0.91
  Group 3: Negative for cardiovascular disease (*N* = 50)                  47                                  3                                    0.94                        0.83--0.99
  Group 4: Negative for cerebrovascular disease (*N* = 50)                 50                                  0                                    1.00                        0.93--1.00
  Group 5: Negative for moderate/severe renal disease (*N* = 50)           47                                  3                                    0.94                        0.83--0.99
  Group 6: Negative for liver disease (*N* = 50)                           49                                  1                                    0.95                        0.89--0.99
  Group 7: Negative for COPD (*N* = 50)                                    46                                  4                                    0.92                        0.81--0.98

COPD: chronic obstructive pulmonary disorder.
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